KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Raw Materials: 2018-2020

  • Amneal Pharmaceuticals' Raw Materials was N/A to $162.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $162.7 million, marking a year-over-year change of. This contributed to the annual value of $172.2 million for FY2019, which is 5.23% down from last year.
  • As of Q1 2020, Amneal Pharmaceuticals' Raw Materials stood at $162.7 million, which was down 5.48% from $172.2 million recorded in Q4 2019.
  • Over the past 5 years, Amneal Pharmaceuticals' Raw Materials peaked at $182.8 million during Q3 2019, and registered a low of $162.7 million during Q1 2020.
  • Its 3-year average for Raw Materials is $174.8 million, with a median of $176.9 million in 2018.
  • Data for Amneal Pharmaceuticals' Raw Materials shows a maximum YoY decreased of 5.23% (in 2019) over the last 5 years.
  • Amneal Pharmaceuticals' Raw Materials (Quarterly) stood at $181.7 million in 2018, then decreased by 5.23% to $172.2 million in 2019, then reached $162.7 million in 2020.
  • Its Raw Materials stands at $162.7 million for Q1 2020, versus $172.2 million for Q4 2019 and $182.8 million for Q3 2019.